trial

Inflammatory Response In Schizophrenia

NCTId NCT03093064
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 66 (actual)
Sponsored by King's College London
Primary completion 2023-06-15
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
66 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2017-04-01
Primary completion
2023-06-15
Eligibility
ALL · 18 Years · 50 Years

Interventions & indications

Drugs
Natalizumab

Sponsors

King's College LondonLead Sponsor
South London and Maudsley NHS Foundation TrustCollaborator

Investigators

1
Oliver D HowesPrincipal Investigator

Sites

1 total
London, United Kingdom

Facts & assertions

4 sourced
Enrollment
66
Phase
PHASE1
Primary Completion Date
2023-06-15
Status
COMPLETED
relationships
The graph out of here
drug
Natalizumab
drug
lead_sponsor
King's College London
company
collaborator
South London and Maudsley NHS Foundation Trust
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Oliver D Howes
person